此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

心脏手术后直接口服抗凝剂与华法林的对比试验 (DANCE)

2026年9月15日 更新者:Population Health Research Institute

The DANCE Trial is a multi-centre, randomized controlled trial comparing the safety of direct oral anticoagulants (DOAC) versus vitamin K antagonists (VKA) in the early period (30 days) after cardiac surgery in patients with atrial fibrillation requiring oral anticoagulation.

研究概览

详细说明

Approximately 36,000 Canadian adults undergo cardiac surgery annually. Of these patients, about 10% have a prior history of atrial fibrillation (AF). In the early post-operative period after cardiac surgery, 30-60% of patients develop AF and, by the time of discharge, 32% of patients who underwent cardiac surgery have an indication for oral anticoagulation (OAC). AF is associated with a significantly higher risk of stroke, even when transient, and OAC is the standard for thromboembolic prevention in these patients. In the post-operative period, the balance of benefits and risks of OAC may differ and the safest and most effective OAC in that patient population is uncertain.

Vitamin K antagonists (VKAs), such as warfarin or coumadin, are the most used anticoagulants after cardiac surgery. In the Left Atrial Appendage Occlusion Study (LAAOS) III that recruited 4811 patients from 105 centres in 27 countries, 77% of patients with AF on OAC were discharged on a VKA after cardiac surgery. Among patients taking a DOAC preoperatively, 55% were switched to a VKA after surgery. Over the first post-operative year, most of those patients were gradually transitioned back to a DOAC. Although effective, the use of VKAs is limited by a narrow therapeutic index requiring frequent international normalized ratio (INR) measurements to ensure appropriate levels of anticoagulation. This key limitation leads to non-compliance and discontinuation. In addition, in the first 3 months after cardiac surgery, time in the therapeutic range is low, even with close monitoring by experienced prescribers.

In the last decade, DOACs - inhibitors of factor Xa or thrombin- have become broadly used in patients with AF. Treatment with a DOAC in patients with AF has been demonstrated to yield a lower risk of stroke or systemic embolism and a similar risk of major bleeding when compared to VKAs during long-term follow-up. Moreover, DOACs are more convenient for both patients and clinicians. They have a rapid onset of effect, fixed dosage that obviates the need for regular monitoring, and few interactions with food and other medications. In the postoperative setting, DOACs may also lead to shorter length of stay and reduced costs.

The purpose of this study is to establish whether DOACs are as safe as VKAs in the first few weeks after heart surgery. The results of this study will impact the treatment of hundreds of thousands of patients in the world every year.

A subset of 910 DANCE participants with a recent bioprosthetic aortic and/or mitral valve replacement will be enrolled in the SUNDANCE substudy (Subclinical valve thrombosis in patients with surgical bioprosthetic valve replacement: An imaging substudy of the DANCE trial). SUNDANCE will examine the effects of DOACs versus VKAs on subclinical valve thrombosis and bioprosthetic valve function by conducting computed tomography (CT) scans and echocardiograms at 60 to 90 days after randomization.

研究类型

介入性

注册 (估计的)

3500

阶段

  • 第三阶段

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

研究联系人备份

学习地点

    • Alberta
      • Edmonton、Alberta、加拿大、T6G 2C8
        • 招聘中
        • University of Alberta Hospital
        • 首席研究员:
          • Steven Meyer, MD
        • 接触:
          • Steven Meyer, MD
    • British Columbia
      • Vancouver、British Columbia、加拿大、V6T 1Z3
        • 招聘中
        • University of British Columbia
        • 首席研究员:
          • Erica Wang, PharmD
    • Manitoba
      • Winnipeg、Manitoba、加拿大、R2H 2A6
        • 招聘中
        • St. Boniface Hospital
        • 首席研究员:
          • Michael Yamashita, MD
        • 接触:
          • Michael Yamashita, MD
    • New Brunswick
      • Saint John、New Brunswick、加拿大、E2L4L2
        • 主动,不招人
        • Saint John Regional Hospital
    • Newfoundland and Labrador
      • St. John's、Newfoundland and Labrador、加拿大、A1B 3V6
        • 招聘中
        • Health Science Centre
        • 首席研究员:
          • Hasib Hanif, MD
    • Ontario
      • Greater Sudbury、Ontario、加拿大、P3E 5J1
        • 招聘中
        • Health Sciences North Research Institute
        • 首席研究员:
          • Bindu Bittira, MD
      • Hamilton、Ontario、加拿大、L8L 2X2
        • 招聘中
        • Hamilton General Hospital
        • 接触:
      • Toronto、Ontario、加拿大、M5G 2C4
        • 招聘中
        • Toronto General Hospital
        • 接触:
          • Vivek Rao, MD
        • 首席研究员:
          • Vivek Rao, MD
      • Toronto、Ontario、加拿大、M4N 3M5
        • 招聘中
        • Sunnybrook Hospital
        • 接触:
          • Stephen Fremes, MD
        • 首席研究员:
          • Stephen Fremes, MD
    • Quebec
      • Montreal、Quebec、加拿大、H1T 1C8
        • 招聘中
        • Montreal Heart Institute
        • 接触:
          • Philippe Demers, MD
        • 首席研究员:
          • Philippe Demers, MD
      • Montreal、Quebec、加拿大、H4J1C5
        • 招聘中
        • Hôpital Sacré-Coeur de Montréal
        • 首席研究员:
          • Hugues Jeanmart, MD
        • 接触:
          • Hugues Jeanmart, MD
      • Québec、Quebec、加拿大、G1V 4G5
        • 招聘中
        • IUCPQ-ULaval
        • 接触:
          • Eric Dumont, MD
        • 首席研究员:
          • Eric Dumont, MD
      • Bonn、德国、53127
        • 主动,不招人
        • University Hospital Bonn Heart Center
      • Essen、德国、45147
        • 尚未招聘
        • West-German Heart and Vascular Center, University of Duisburg-Essen
        • 接触:
          • Matthias Thielmann, MD, PhD
        • 首席研究员:
          • Matthias Thielmann, MD, PhD
      • Hamburg、德国、20246
        • 招聘中
        • University Medical Center Hamburg-Eppendorf
        • 接触:
          • Simon Pecha, MD
        • 首席研究员:
          • Simon Pecha, MD
    • Saxony
      • Leipzig、Saxony、德国、04289
        • 主动,不招人
        • Heart Center Leipzig
    • Thuringia
      • Jena、Thuringia、德国、Germany
        • 招聘中
        • University Hospital Jena
        • 接触:
          • Torsten Doenst, MD, PhD
        • 首席研究员:
          • Torsten Doenst, MD, PhD
    • Victoria
      • Fitzroy、Victoria、澳大利亚、3065
        • 招聘中
        • St Vincent's Hospital Melbourne
        • 接触:
          • Andrew Newcomb, MD
        • 首席研究员:
          • Andrew Newcomb, MD
      • Parkville、Victoria、澳大利亚、3050
        • 尚未招聘
        • Royal Melbourne Hospital, University of Melbourne
        • 接触:
          • Alistair Royse, MD
        • 首席研究员:
          • Alistair Royse, MD

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  1. Age ≥18 years at the time of enrolment,
  2. Open heart surgery in the last 10 days,
  3. Atrial fibrillation requiring anticoagulation (including pre-existing or post-operative atrial fibrillation),
  4. Informed consent from either the patient or a substitute decision-maker.

Exclusion Criteria:

  1. Mechanical valve replacement,
  2. Antiphospholipid syndrome (triple positive),
  3. Severe renal failure (Cockcroft-Gault equation; creatinine clearance <15 ml/min),
  4. Known significant liver disease (Child-Pugh classification B and C),
  5. Left ventricular thrombus,
  6. Ongoing bleeding, hemorrhagic disorders, or bleeding diathesis,
  7. Known contraindication for any DOAC or VKA,
  8. Women who are pregnant, breastfeeding, or of childbearing potential,
  9. Surgery including left ventricular assist device implantation or cardiac transplantation,
  10. Previously enrolled in this trial,
  11. Follow-up not possible,
  12. History of moderate or severe mitral valvular lesion (stenosis or regurgitation) that is not corrected during index cardiac surgery.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:随机化
  • 介入模型:阶乘赋值
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
有源比较器:Direct Oral Anticoagulation (DOAC)

Patients in the intervention group will receive a DOAC at doses recommended for the indication, adjusted for their renal function is required. The choice of DOAC will be at the discretion of the treating physician.

Patients will receive a DOAC at doses recommended for the indication, adjusted for their renal function is required. The choice of DOAC will be at the discretion of the treating physician.

其他名称:
  • 阿哌沙班
  • 达比加群酯
  • 依度沙班
  • 利伐沙班
安慰剂比较:Vitamin K Antagonist

Patients in the control group will receive VKA once daily; the individual dose will be titrated to achieve a guideline-recommended INR range.

Patients in the control group will receive VKA once daily; the individual dose will be titrated to achieve a guideline-recommended INR range.

其他名称:
  • 华法林

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Major Bleeding
大体时间:30-Days post-randomization

Major bleeding at 30 days, defined as bleeding that results in death and/or symptomatic bleeding in a critical area or organ, bleeding into a surgical site requiring reoperation, bleeding leading to hospitalization (including presentation to an acute care facility without overnight stay) and/or bleeding that causes a drop in the hemoglobin level of 20g/L or more or that which requires the transfusion of ≥2 units of packed red blood cells or whole blood (as defined by the International Society of Thrombosis and Hemostasis)

30-Days post-randomization

次要结果测量

结果测量
大体时间
中风和非中枢神经系统全身动脉栓塞在 30 天和 90 天时的综合情况。
大体时间:随机分组后 30 天和 90 天
随机分组后 30 天和 90 天
大出血
大体时间:随机化后 90 天
随机化后 90 天
需要引流的胸膜或心包积液
大体时间:随机分组后 30 天和 90 天
随机分组后 30 天和 90 天
全身动脉栓塞
大体时间:随机分组后 30 天和 90 天
随机分组后 30 天和 90 天
缺血性中风
大体时间:随机分组后 30 天和 90 天
随机分组后 30 天和 90 天
深静脉血栓形成
大体时间:随机分组后 30 天和 90 天
随机分组后 30 天和 90 天
肺栓塞
大体时间:随机分组后 30 天和 90 天
随机分组后 30 天和 90 天
术后住院时间
大体时间:随机分组后 30 天和 90 天
随机分组后 30 天和 90 天
全因死亡率
大体时间:随机分组后 6 个月
随机分组后 6 个月

其他结果措施

结果测量
措施说明
大体时间
心肌梗塞
大体时间:随机分组后 30 天和 90 天
随机分组后 30 天和 90 天
亚临床瓣膜血栓形成与有临床意义的主动脉瓣血栓形成、中风或全身性栓塞之间的关联
大体时间:90天
90天
Minor Bleeding
大体时间:30-Days and 90-Days post-randomization

Tertiary outcome

30-Days and 90-Days post-randomization
All bleeding (major plus minor)
大体时间:30-Days and 90-Days post-randomization

Tertiary outcome

30-Days and 90-Days post-randomization
Valve Thrombosis
大体时间:30-Days and 90-Days post-randomization

Tertiary outcome

30-Days and 90-Days post-randomization
Hemorrhagic stroke
大体时间:30-Days and 90-Days post-randomization

Tertiary outcome

30-Days and 90-Days post-randomization
All Stroke
大体时间:30-Days and 90-Days post-randomization

Tertiary outcome

30-Days and 90-Days post-randomization
All Arterial Thrombosis/thromboembolism
大体时间:30-Days and 90-Days post-randomization

Tertiary outcome: ischemic stroke, systemic arterial embolism, myocardial infarction, valve thrombosis

30-Days and 90-Days post-randomization
Quality of Life - EQ-5D-5L
大体时间:30-Days and 90-Days post-randomization

Tertiary outcome: Measured by The EQ-5D-5L Questionnaire

30-Days and 90-Days post-randomization
Patient Satisfaction with Anticoagulant treatment
大体时间:30-Days and 90-Days post-randomization

Tertiary outcome: Assessed by the Perception of Anticoagulant Treatment Questionnaire

30-Days and 90-Days post-randomization
Subclinical Valve Thrombosis on CT scan
大体时间:60 to 90-Days post-randomization

Substudy outcome

60 to 90-Days post-randomization
Mean Aortic Valve g=Gradient on echocardiogram
大体时间:60 to 90-Days post-randomization

Substudy outcome

60 to 90-Days post-randomization
Aortic Valve Reintervention
大体时间:60 to 90-Days post-randomization

Substudy outcome

60 to 90-Days post-randomization

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 首席研究员:Emilie Belley-Cote, MD, MSc、McMaster University

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2021年7月18日

初级完成 (估计的)

2027年6月1日

研究完成 (估计的)

2027年6月1日

研究注册日期

首次提交

2020年2月24日

首先提交符合 QC 标准的

2020年2月24日

首次发布 (实际的)

2020年2月26日

研究记录更新

最后更新发布 (实际的)

2026年9月18日

上次提交的符合 QC 标准的更新

2026年9月15日

最后验证

2025年9月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

IPD 计划说明

We will establish a plan for the full-scale study but there is no plan to make IPD available to other researchers.

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

在美国制造并从美国出口的产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅